MedTrace Logo

Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)

NCT00119457 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2009-06-03

No results posted yet for this study

Summary

The purpose of this study is to determine whether TTP889 prevents venous thromboembolism following surgery to repair hip fracture.

Conditions

  • Venous Thromboembolism
  • Embolism and Thrombosis
  • Hip Fractures

Interventions

DRUG

TTP889

Sponsors & Collaborators

  • vTv Therapeutics

    lead INDUSTRY

Principal Investigators

  • Bengt I Eriksson, MD · Dept of Orthopaedics, Goteborg University

  • David P Ward, MD · vTv Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Completion
2006-04-30

Countries

  • Czechia
  • Denmark
  • Norway
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00119457 on ClinicalTrials.gov